 CAMBRIDGE, Mass.--BUSINESS WIRE--Gemini Therapeutics, Inc. Nasdaq: GMTX, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration AMD, today reported its financial results for the year ended December 31, 2020 and provided a business update. The past 12 months have been truly transformative for Gemini as we successfully transitioned to a publicly traded precision medicine company with a strong balance sheet and r 